RSS SubscribeMay 11, 2021
Vancouver, British Columbia–(Newsfile Corp. – May 11, 2021) – Entheon Biomedical Corp. (CSE: ENBI) today announced that, Timothy Ko, CEO of Entheon, will be attending the Q2 Virtual Investor Summit.
| Event | Q2 Investor Summit |
| Date | May 17-18th, 2021 |
| Presentation | May 17th at 10:15 AM ET |
| Location | https://zoom.us/webinar/register/WN_qt5qaIR9SyODcSgsjZOfqw |
About Entheon Biomedical Corp.
Entheon Biomedical is a drug development and biotechnology company whose primary aim is to provide solutions for people battling addiction so they can reclaim their lives and potential. With a focus on advancing the therapeutic potential of the DMT molecule through clinical trials and a traditional regulatory framework, Entheon is also developing specialized tools to personalize care, from patient assessment to psychedelic treatment and beyond. Entheon believes a comprehensive and holistic approach to care will significantly increases the odds of permanent recovery for those struggling with addiction disorders.